Sign In
Buy DGX
$233.72
+1.77 (+0.763%)
At Close: Aug 04, 2026
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:39am, Thursday, 14'th Jul 2022
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?
04:00pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.
Quest Diagnostics to launch monkeypox test in August
07:48am, Wednesday, 13'th Jul 2022
Quest Diagnostics Inc. DGX, -1.38% said Wednesday that it developed a monkeypox test that it plans to launch in August. The PCR test, which is administered by a physician, can detect monkeypox and als
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
02:41pm, Monday, 11'th Jul 2022 Zacks Investment Research
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
12:22pm, Monday, 11'th Jul 2022
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
02:33pm, Friday, 01'st Jul 2022 Zacks Investment Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
12:18pm, Friday, 01'st Jul 2022
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss
05:53pm, Thursday, 30'th Jun 2022 Zacks Investment Research
Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.
Option Care (OPCH) Stock Jumps 5.6%: Will It Continue to Soar?
10:02am, Monday, 27'th Jun 2022 Zacks Investment Research
Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Quest Diagnostics to Release Second Quarter 2022 Financial Results on July 21, 2022
04:09pm, Friday, 24'th Jun 2022
SECAUCUS, N.J. , June 24, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarte
7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches On
06:06pm, Thursday, 23'rd Jun 2022
Even if the market has not yet reached the point of bottoming-out, these seven undervalued large-cap stocks are worth a look. The post 7 Undervalued Large-Cap Stocks to Buy Before Wall Street Catches
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
01:40pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Quest Diagnostics: Not Appealing Yet, Despite The Downturn
01:29pm, Wednesday, 22'nd Jun 2022
Quest Diagnostics is a company I've been covering for a number of years, and one I wished I'd invested deeper in during the COVID-19 crash. We might be in for an opportunity to load up on a quality co
Quest Diagnostic Stock is Ready to Move Higher
05:00am, Tuesday, 21'st Jun 2022
Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been performing relatively stronger than the benchmark indices down only (-20%) on the year.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
02:38pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
